FDA Introduces Electronic Submissions Gateway

Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Food and Drug Administration has opened the FDA Electronic Submissions Gateway (ESG) to receive and process regulatory submissions to the Center For Biologics Evaluation and Research, the Center for Drug Evaluation and Research, and the Center for Devices and Radiological Health.

The US Food and Drug Administration (Rockville, MD, www.fda.gov) has opened the FDA Electronic Submissions Gateway (ESG) to receive and process regulatory submissions to the Center for Biologics Evaluation and Research, the Center for Drug Evaluation and Research, and the Center for Devices and Radiological Health.

FDA announced the availability of ESG in a notice in the Aug. 8 Federal Register (1). The FDA ESG enables applicants to send applications and other submissions for review using the Internet and provides a single point of entry for these submissions. The FDA ESG automates the receipt, acknowledgement to the applicant or sponsor, routing, and notification to a receiving center of the electronic submission via the Internet.

The use of the FDA ESG is voluntary. Electronic-format submissions may be made through the gateway or may continue to be made on physical media. Except where FDA has promulgated regulations requiring submissions in electronic format, applicants also may continue to make regulatory submissions on paper.

The FDA ESG offers two communication options for applicants that have established gateway systems. One uses simple mail transfer protocol (SMTP) with secure multipurpose Internet mail extensions (S/MIME) to provide secure e-mail communications. The other supports faster information exchange and uses hypertext transfer protocol secure (HTTPS) to provide real-time Internet communication. The FDA ESG also offers a secure WebTrader submission option for applicants who do not have gateway systems.

Reference


1. US Food and Drug Administration, "Food and Drug Administration Electronic Gateway Submission," Fed. Regist. 71 (152), 45057 (Aug. 8, 2006). 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes